Mygalin, an Acanthoscurria gomesiana spider-derived synthetic, modulates haloperidol-induced cataleptic state in mice.

Acanthoscurria gomesiana spider Haloperidol Mygalin, catalepsy Natural compounds

Journal

Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130

Informations de publication

Date de publication:
08 Dec 2023
Historique:
received: 22 06 2023
revised: 22 11 2023
accepted: 26 11 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 10 12 2023
Statut: aheadofprint

Résumé

Haloperidol (HAL) is an antipsychotic used in the treatment of schizophrenia. However, adverse effects are observed in the extrapyramidal tracts due to its systemic action. Natural compounds are among the treatment alternatives widely available in Brazilian biodiversity. Mygalin (MY), a polyamine that was synthesized from a natural molecule present in the hemolymph of the Acanthoscurria gomesian spider, may present an interesting approach. This study aimed to evaluate the effect of MY in mice subjected to HAL-induced catalepsy. Male Swiss mice were used. Catalepsy was induced by intraperitoneal administration of HAL (0.5 mg/kg - 1 mL/Kg) diluted in physiological saline. To assess the MY effects on catalepsy, mice were assigned to 4 groups: (1) physiological saline (NaCl 0.9 %); (2) MY at 0.002 mg/Kg; (3) MY at 0.02 mg/Kg; (4) MY at 0.2 mg/Kg. MY or saline was administered intraperitoneally (IP) 10 min b HAL before saline. Catalepsy was evaluated using the bar test at 15, 30, 60, 90, and 120 min after the IP administration of HAL. The latency time in the bar test 15, 30, 60, and 90 min increased (p < 0.05) after IP administration of HAL compared to the control group. Catalepsy was attenuated 15, 30, 90, and 120 min (p < 0.05) after the IP-administration of MY at 0.2 mg/Kg; while MY at 0.02 mg/Kg attenuated catalepsy 15 min after the HAL treatment. Our findings showed that MY attenuates the HAL-induced cataleptic state in mice.

Sections du résumé

BACKGROUND BACKGROUND
Haloperidol (HAL) is an antipsychotic used in the treatment of schizophrenia. However, adverse effects are observed in the extrapyramidal tracts due to its systemic action. Natural compounds are among the treatment alternatives widely available in Brazilian biodiversity. Mygalin (MY), a polyamine that was synthesized from a natural molecule present in the hemolymph of the Acanthoscurria gomesian spider, may present an interesting approach.
AIMS OBJECTIVE
This study aimed to evaluate the effect of MY in mice subjected to HAL-induced catalepsy.
METHODS METHODS
Male Swiss mice were used. Catalepsy was induced by intraperitoneal administration of HAL (0.5 mg/kg - 1 mL/Kg) diluted in physiological saline. To assess the MY effects on catalepsy, mice were assigned to 4 groups: (1) physiological saline (NaCl 0.9 %); (2) MY at 0.002 mg/Kg; (3) MY at 0.02 mg/Kg; (4) MY at 0.2 mg/Kg. MY or saline was administered intraperitoneally (IP) 10 min b HAL before saline. Catalepsy was evaluated using the bar test at 15, 30, 60, 90, and 120 min after the IP administration of HAL.
RESULTS RESULTS
The latency time in the bar test 15, 30, 60, and 90 min increased (p < 0.05) after IP administration of HAL compared to the control group. Catalepsy was attenuated 15, 30, 90, and 120 min (p < 0.05) after the IP-administration of MY at 0.2 mg/Kg; while MY at 0.02 mg/Kg attenuated catalepsy 15 min after the HAL treatment. Our findings showed that MY attenuates the HAL-induced cataleptic state in mice.

Identifiants

pubmed: 38072029
pii: S0304-3940(23)00531-1
doi: 10.1016/j.neulet.2023.137572
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

137572

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gabriela Xavier Santos (GX)

Physiotherapy Department, Federal University of Alfenas (UNIFAL), Alfenas, Brazil.

Joyce Elise Dos SantosTeodoro (JE)

Physiotherapy Department, Federal University of Alfenas (UNIFAL), Alfenas, Brazil.

Mylena Gonçalves Fonseca (MG)

Physiotherapy Department, Federal University of Alfenas (UNIFAL), Alfenas, Brazil.

Renata Moreira Acunha (RM)

Laboratory of Neurosciences of Pain & Emotions and Multi-User Center of Neuroelectrophysiology, Department of Surgery and Anatomy, Ribeirão Preto Medical School of the University of São Paulo, Av. Bandeirantes 3900 Ribeirão Preto, São Paulo 14049-900, Brazil.

Pedro Ismael da Silva Júnior (PI)

Laboratory for Applied Toxinology (LETA), Butantan Institute, Sao Paulo, SP 05503-900, Brazil.

Luciana Maria Dos Reis (LMD)

Physiotherapy Department, Federal University of Alfenas (UNIFAL), Alfenas, Brazil. Electronic address: reislucianamaria@g.com.

Renato Leonardo de Freitas (RL)

Laboratory of Neurosciences of Pain & Emotions and Multi-User Center of Neuroelectrophysiology, Department of Surgery and Anatomy, Ribeirão Preto Medical School of the University of São Paulo, Av. Bandeirantes 3900 Ribeirão Preto, São Paulo 14049-900, Brazil; Interdisciplinary Center for Pain Care, Federal University of São Carlos (UFSCar), Universidade Federal de São Carlos, Rodovia Washington Luiz, Km 235, Caixa Postal 676, CEP 13565-905, SP, Brazil; Behavioural Neurosciences Institute (INeC), Av. do Café 2450 Ribeirão Preto, São Paulo 14050-220, Brazil.

Priscila Medeiros (P)

Interdisciplinary Center for Pain Care, Federal University of São Carlos (UFSCar), Universidade Federal de São Carlos, Rodovia Washington Luiz, Km 235, Caixa Postal 676, CEP 13565-905, SP, Brazil; Department of General and Specialized Nursing - EERP/USP Ribeirão Preto College of Nursing - USP, Brazil; Behavioural Neurosciences Institute (INeC), Av. do Café 2450 Ribeirão Preto, São Paulo 14050-220, Brazil. Electronic address: priscila.neuro@usp.br.

Classifications MeSH